Effects of Stimulants on Behavioral and Neural Markers of Social Motivation, Ability, and Neural Markers of Social Function
NCT ID: NCT05379959
Last Updated: 2024-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
43 participants
INTERVENTIONAL
2022-05-11
2023-10-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Stimulant Drugs on Social Perception
NCT03790618
Effects of Drugs on Responses to Brain and Emotional Processes
NCT04053036
Effects of MDMA and Methylphenidate on Social Cognition
NCT01616407
Prosocial Effects of MDMA
NCT05948683
Effects of MDMA on Social and Emotional Processing
NCT01849419
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental: Placebo Then MDMA Then Methamphetamine
Participants first receive placebo at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive 125 mg MDMA. Finally, 5 days later will return to the laboratory and will receive 20 mg of MA.
MDMA
Participants will be given 125 mg of MDMA.
Methamphetamine
Participants will be given 20 mg of MA.
placebo oral tablet
Participants will be given a placebo capsule that will only contain lactose.
Experimental: MDMA Then Placebo Then Methampetamine
Participants first receive 125 mg of MDMA at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive placebo. Finally, 5 days later will return to the laboratory and will receive 20 mg of MA.
MDMA
Participants will be given 125 mg of MDMA.
Methamphetamine
Participants will be given 20 mg of MA.
placebo oral tablet
Participants will be given a placebo capsule that will only contain lactose.
Experimental: Methampetamine Then Placebo Then MDMA
Participants first receive 20 mg of MA at their first session in the laboratory. Then will return to the laboratory 5 days later and will receive placebo. Finally, 5 days later will return to the laboratory and will receive 125 mg of MDMA.
MDMA
Participants will be given 125 mg of MDMA.
Methamphetamine
Participants will be given 20 mg of MA.
placebo oral tablet
Participants will be given a placebo capsule that will only contain lactose.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MDMA
Participants will be given 125 mg of MDMA.
Methamphetamine
Participants will be given 20 mg of MA.
placebo oral tablet
Participants will be given a placebo capsule that will only contain lactose.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Smokers smoking less than 25 cigarettes per week
* Have used ecstasy no more than 40 times with no adverse responses.
Exclusion Criteria
* Any medical condition requiring regular medication
* Individuals with a current (within the last year) DSM-IV Axis 1 diagnosis
* Individuals with a history of dependence on stimulant drugs.
* Women who are pregnant or trying to become pregnant
18 Years
40 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Chicago
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Chicago
Chicago, Illinois, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB21-1568
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.